Licensing Agreement for GnRH Antagonist Linzagolix with Synmosa Biopharma Corporation in Taiwan

Kissei Pharmaceutical Co., Ltd. (Head Office: Matsumoto, Nagano; Chairman and CEO: Mutsuo Kanzawa; "Kissei") announced that it has entered into a license agreement with Synmosa Biopharma Corporation (Head Office: Taiwan, CEO: Peter Lin; "Synmosa") to license development and commercialization rights in Taiwan for the GnRH antagonist linzagolix that was discovered by Kissei.

By executing this agreement, in Taiwan, Synmosa will develop and commercialize linzagolix. Kissei will receive an upfront payment, milestone payments based on the progress of the development conducted and royalty payments according to the sales of product by Synmosa.

Linzagolix is a novel, orally administered GnRH (gonadotropin releasing hormone) receptor antagonist. Linzagolix acts by antagonizing GnRH at the GnRH receptor in the pituitary gland and consequently suppressing the secretion of gonadotropin. Ultimately reducing estrogen production at the ovaries, it improves symptoms of uterine fibroids and endometriosis.

In Japan, Kissei has initiated Phase III clinical trial for uterine fibroids. In the EU, linzagolix received marketing authorization for uterine fibroids in June 2022. Bio Genuine (China) which has exclusive development and commercialization rights for China, is under preparation to start clinical trials.

Kissei focuses on drug discovery, research and development of new drugs. In collaboration with partner companies, Kissei will contribute to the health of people around the world through developing novel drugs.

The upfront income is triggered by this agreement, and it has negligible effects on Kissei's consolidated business forecasts for the fiscal year ending in March 2023.

《 Reference 》

About Synmosa Biopharma Corporation
Synmosa Biopharma Corporation, a listed company in Taiwan OTC stock market (TW.4114), was founded in 1980. Synmosa focus various therapeutic areas of expertise such as cardiovascular, respiratory, woman healthcare, urology, oncology, and CNS. We develop sustainable business ranging from R&D, manufacturing, contract manufacturing as well as sales and distribution for both pharmaceuticals and health supplements.
For more information, please visit http://www.synmosa.com.tw/EN/home/Default.asp